Bridging Sunitinib Exposure to Time‐to‐Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. (8th June 2016)

• Record Type: Journal Article
• Authors: Ait‐Oudhia, S; Mager, DE; Pokuri, V; Tomaszewski, G; Groman, A; Zagst, P; Fetterly, G; Iyer, R
• Is Part Of: CPT: pharmacometrics & systems pharmacology. Volume 5:Number 6(2016:Jun.)
• Page Start: 297
• Page End: 304
• Publication Date: 2016-06-08
• Subjects: Pharmacokinetics -- Periodicals; Pharmacology -- Periodicals; Pharmacokinetics; Periodicals; 615.05
• DOI: 10.1002/psp4.12084
• Languages: English
• ISSNs: 2163-8306

Abstract

Abstract : Hepatocellular carcinoma (HCC) is third in cancer‐related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a selective tyrosine kinase inhibitor of the angiogenic biomarker: soluble vascular endothelial growth factor receptor‐2 (sVEGFR2 ). Sunitinib failed its primary overall survival endpoint in patients with advanced HCC in a phase III trial compared to sorafenib. In the present study, pharmacokinetic‐pharmacodynamic modeling was used to link drug‐exposure to tumor‐growth‐inhibition (TGI) and time‐to‐tumor progression (TTP) through sVEGFR2 dynamics. The results suggest that 1) active drug concentration (i.e., sunitinib and its metabolite) inhibits the release of sVEGFR2 and that such inhibition is associated with TGI, and 2) daily sVEGFR2 exposure is likely a reliable predictor for the TTP in HCC patients. Moreover, the model quantitatively links the dynamics of an angiogenesis biomarker to TTP and accurately predicts observed literature‐reported results of placebo treatment.